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Abstract  
Aim: Using Australian guidelines for management of acute coronary syndromes (ACS), we assessed the 
probability of an Indigenous patient receiving interventional and therapeutic care after presenting in two 
metropolitan hospitals.  
Methods: A retrospective case note review of patients admitted through two Adelaide public tertiary 
hospital emergency departments from December 2007 to December 2009. The study cohort was 488 
patients with high-risk clinical features without ST-segment-elevation.   
Results: Indigenous patients were significantly younger, present later in the disease process and have 
a higher burden of cardiovascular risk factors, when compared to non-Indigenous patients. Indigenous 
patients were 54% more likely to receive angiography (RR=1.54; 95% CI 1.31;1.81) than non-
Indigenous patients however this difference disappeared after adjustment for age, sex and propensity 
score.  Indigenous patients were 20% more likely to receive the recommended medications (RR=1.19, 
95% CI 1.01;1.40) compared to non-Indigenous patients. Patients over 65 years were 53% less likely 
to receive an angiogram (RR=0.47, 95% CI 0.38;0.56) and were 35% less likely to receive the 
recommended medications (RR=0.65, 95% CI 0.54;0.78) than a patient at the ages of 18-49. Women 
were almost 20% less likely to receive an angiogram (RR=0.81, 95% CI 0.66;0.99) and 20% less 
likely to receive the recommended medications (RR=0.80, 95% CI 0.71;0.91) when compared to men. 
The likelihood of receiving medications on discharge was significantly influenced by age, gender, 
ethnicity, comorbid burden and revascularisation.  
Conclusions: The younger age and significantly higher risk profile of Indigenous adults presenting to 
SA hospitals with ACS appears to lead to different management decisions, which may well be led by 
patient factors. Many of these risk conditions can be better managed in the primary care setting.  
Keywords: Indigenous, gender, age, therapeutic intervention, diagnostic coronary angiography, acute 
coronary syndromes 
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Introduction 
Compared to other Australians, Indigenous people are three times more likely to have a coronary 
event, 40% more likely to have out-of-hospital-death from coronary heart disease and  40% less likely 
to be investigated by angiography.
[1]
 This is problematic as cardiovascular disease (CVD) followed by 
diabetes accounts for one-fifth of the health ‘gap’ in shortened life expectancy experienced by 
Indigenous Australians. Indigenous people at the ages of 35-44 years are 9-12 times more likely to die 
from CVD than non-Indigenous Australians.
[2]
 
The few studies that examine revascularisation rates after an acute cardiac event comparing 
Indigenous patients and non-Indigenous patients report mixed results.
[2-4]
 We assessed the probability 
of an Indigenous patient receiving Australian guideline-concordant interventional and therapeutic care 
for acute coronary syndromes (ACS) after presenting at two metropolitan Australian hospitals. The 
outcome of interest was whether Indigenous patients diagnosed with non ST-segment elevation acute 
coronary syndromes (NSTEACS) received diagnostic coronary angiography and discharge 





We conducted a retrospective case note review of patients admitted through two Adelaide 
metropolitan public tertiary hospital emergency departments from December 2007 to December 2009 
who were categorised as having high-risk NSTEACS.  Inclusion criteria included persistent ECG 
changes of ST-segment depression, haemodynamic compromise, prior coronary intervention within 6 
months, presence of known diabetes and elevated level of at least 1 cardiac biomarker.
[5]  
 
The variables extracted from in-hospital patient medical records included demographic data, history 
of CVD, clinical presentation, and in-hospital treatment. The sample cohort consisted of 3941 non-
Indigenous and 159 Indigenous patients (Figure 1). To provide clinical significance sample sizes of 85 
Indigenous patients and 403 non-Indigenous patients were used to achieve 80% power to detect a rate 
ratio for each outcome measure of 1.2. The rate in the Indigenous group is assumed be 0.60 under the 
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null hypothesis and 0.72 under the alternative hypothesis. The rate in the non-Indigenous group is 0.6. 
The significance level of the test was targeted at 0.05. At both study sites, Indigenous status was 
identified in the hospital administrative database and confirmed by a manual review of the patient 
medical records.  
Guidelines for the management of ACS 
The Australian guidelines for the management of ACS recommend that patients at high-risk of a 
secondary cardiac event (except those with severe comorbidities) undergo angiography. The 
procedure examines the cause of acute ischaemia and the extent of underlying coronary artery disease 
(CAD), consequently influencing patient management.
[7] 
In addition, the guidelines recommend 
medications that should be prescribed before discharge for high-risk patients: aspirin, clopidogrel, 
angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist, β blocker and statin.  If at 
least three of the five recommended medications were prescribed to the patient on discharge, the care 
was assessed as guideline-concordant.  
Propensity Score 
To account for potential confounders
[7]
, a propensity score was calculated based on cardiovascular 
risk factors (hypertension, diabetes, smoking status); history of previous infarction; percutaneous or 
surgical revascularisation; peripheral artery disease; and troponin release. Logistic regression with 
Indigenous status as the dependent variable was used to create the propensity score. 
Adjusting for Age 
The Australian Indigenous population is relatively young and characterized by higher fertility and 
lower life expectancy than the non-Indigenous population.
 [8]
  Life expectancy at birth for males is 59 
years and 65 years for females, with the most recent estimate of an 11 year life expectancy ‘gap’ when 
compared to non-Indigenous Australians.
[8]
  In addition, health disparities between Indigenous and 
non-Indigenous populations are not constant over the life course. Higher mortality rates for 
Indigenous people in potentially the most productive years of their life, add to the differing population 
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structures in the groups.
[9-12] 
We adjusted for age as it is almost certainly a confounding variable. 
Because of this, age was used as a separate covariate rather than including it in the propensity score.  
Analysis 
We used risk ratios (RRs) to estimate the likelihood of having angiography and medications on 
discharge among Indigenous patients compared to non-Indigenous patients. We included descriptive 
and multivariate analyses. The descriptive analysis includes the health profile of the study populations 
by gender and age as well as comorbidities and risk factors that may be associated with angiography 
and discharge medications. We applied a 3-step approach to develop the model-based estimate. Model 
1 is an unadjusted univariate analysis with Indigenous status as the independent variable, Model 2 is 
Model 1 adjusted for age, and Model 3 is Model 1 adjusted for age and propensity score. Log 
binomial generalized linear models were primarily used, and replaced with robust Poisson models in 
the case of non-convergence.  
Results 
Descriptive Analysis 
Description of the study population 
The clinical characteristics of the 85 Indigenous subjects with high-risk NSTEACS and 403 non-
Indigenous high-risk patients are presented in Table 1.  The Indigenous cohort was substantially 
younger, more likely diabetic, and or known to have coronary artery disease (CAD). Current smoking 
rates were much higher for Indigenous patients regardless of gender compared to non-Indigenous 
patients. Notably, a higher proportion of Indigenous patients received an angiogram compared to non-
Indigenous patients. A larger proportion of Indigenous women received an in-hospital 
revascularisation procedure i.e. percutaneous coronary intervention (PCI) and coronary artery bypass 
graft (CABG).  Almost half of the non-Indigenous patients were re-hospitalised within 12 months of 
discharge. There were more in-hospital deaths of non-Indigenous patients and a larger proportion died 
within 12 months of initial hospital discharge.  
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Age, comorbidity and risk factor profile 
When stratified by age-group, comorbidity, risk factors and Indigenous status, 82% of Indigenous 
patients were under 64 years of age compared to just an over a third of non-Indigenous patients.  
Indigenous patients accrued comorbidities earlier, notably diabetes and hypertension.   Both groups 
had a similar proportion of high risk features that may influence the onset of a second acute cardiac 
event (Table 2). 
Diagnostic Angiogram 
Table 3 shows the bivariate analysis that examined factors associated with angiogram including age, 
ethnicity, transfer to metropolitan hospital, lifestyle risk factors and revascularisation. Patients over 65 
years were 53% less likely to receive an angiogram than those aged 18-49 years (RR=0.47, 95% CI 
0.38;0.56). Women were 19% less likely than men to receive an angiogram (RR=0.81, 95% CI 
0.66;0.99). Patients with known CAD were 24% less likely to receive angiography than patients 
without known CAD (RR=0.76, 95% CI 0.63;0.91). A current smoker was 52% more likely to 
undergo angiography than a non-smoker (RR=1.52, 95% CI 1.29-1.79). A patient with prior PCI was 
over twice as likely to have an angiogram than a patient without prior PCI (RR=2.27, 95% CI 
0.1.59;3.24). A patient who received angiography was 40% less likely to die within 12 months of 
discharge than a patient who did not receive angiography (RR=0.63, 95% CI 0.27;0.1.46).  
Medication on Discharge 
The likelihood of receiving medications on discharge was significantly influenced by age, gender, 
ethnicity, comorbid burden and revascularisation. A patient over 65 years was 35% less likely than a 
patient at the ages of 18-49 years to receive the recommended medications (RR=0.65, 95% CI 
0.54;0.78). Women were almost 20% less likely to receive the recommended medications (RR=0.80, 
95% CI 0.71;0.91) while Indigenous patients were almost 50% more likely to receive recommended 
medications (RR=1.49, 95% CI 1.30;1.71). Patients with diabetes were more likely to receive 
medications on discharge. A patient who had received percutaneous (RR=1.62, 95% CI 1.45;1.81) or 
surgical revascularisation (RR=1.30, 95% CI 1.05;1.61) was more likely to receive medications on 
discharge.  
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 Multivariate Analysis 
The results of the generalized linear models are presented in Table 5. For angiography, Model 1 
demonstrates that Indigenous patients are over 50% more likely than non-Indigenous patients to 
receive angiography. However, adjustment for age, sex and propensity score reduced this effect to 
non-significant (RR 0.92, 95% CI 0.75;1.13).  
The relationship between Indigenous status and recommended medications illustrated more variation 
between the models. Model 1 demonstrates that Indigenous patients are almost 50% more likely to 
receive the recommended medications. Adjustment for age, sex and propensity score reduced this 
effect but still demonstrated that Indigenous patients were almost 20% more likely to receive the 
correct medication (RR=1.19, 95 % CI 1.01;1.40).    
Discussion 
Our study found that Indigenous subjects are significantly younger, present later in the disease process 
and have a higher burden of cardiovascular risk factors, when compared to non-Indigenous patients. 
While there was access to angiography and an appropriately higher use of guideline-based medication 
therapy for Indigenous patients, adjustment for their substantially younger age revealed a slightly 
lower likelihood of undergoing angiography, despite an equivalent use of medications.  
There are two main reasons for performing coronary angiography in the setting of high risk 
NSTEACS; as a prelude to revascularisation to mitigate the risk for further events, or, to a much 
lesser extent, as a diagnostic test where there is doubt associated with underlying pathophysiology.
[5]
 
However, there are a number of factors that impact on the likelihood of angiography being performed, 
including accessibility to the service, clinician familiarity with existing treatment guidelines, 
consideration of procedural risk versus benefit, and patient preference.
[5, 13]
 Procedural risk is 
determined by the extent of comorbid disease in the individual patient, while benefit is determined by 
the level of risk imposed by not intervening. In practice, clinicians tend to adopt an interventional 
approach when procedural risk is deemed lower, and this lower risk may carry greater weight in 
decision making than the consideration of benefit. As risk increases, (characterised by increasing age, 
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increasing burden of diabetes, renal disease and increasing comorbidities) the use of angiography 
declines and management tends towards medical therapy as an initial strategy.
[5, 14-16]
 It is possible 
clinicians are more inclined to be influenced by procedural risk than the overall risk profile of the 
patient for secondary events. Decision making may also be influenced by the knowledge that less than 
half of patients undergoing angiography actually proceed to revascularisation, with much of the risk 
mitigation for secondary events being driven by appropriate medical therapy. 
The Indigenous cohort in this study had a higher level of comorbid disease, despite a significantly 
younger mean age, and this may have influenced the rate of angiography. Usually, increasing age 
would be expected to have an inverse relationship with angiography use, largely influenced by the 
increasing burden of comorbidities as people age.
[7]
 The premature accrual of comorbidities in 
Indigenous subjects appears to strongly and negatively influence the use of angiography, more-so than 
the influence that age may usually have on decision making about treatment regimes. There are other 
factors influencing the use of angiography that are not well understood, such as the observed lower 
rate of angiography for females with high risk ACS.
[17, 18]
 Interestingly, Indigenous females in the 
current study were just as likely as Indigenous males to undergo angiography, and more likely than 
non-Indigenous females to undergo angiography. This suggests that the observation of a lack of 
protection by female gender in the Indigenous population studied was recognised and impacted 
clinical decisions.  
In contrast to angiography, evidence-based medical therapy is widely available, generally well 
tolerated and utilised in patients with both low and high burdens of comorbid conditions. The use of 
guideline-based medical therapy is largely determined by clinician familiarity with guidelines and 
patient tolerance of medications.
[5]
 Indigenous patients were more likely to receive guideline-
compliant medications than non-Indigenous patients. This may be in response to the higher burden of 
comorbidities, prompting an increased likelihood of prescribing pharmacological therapies, or, 
clinicians may have adopted a more aggressive approach to medication therapies to compensate for  
reduced access to angiography.
[19]
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This study demonstrates that Indigenous patients presenting with high risk NSTEACS have the same 
likelihood of access to angiography as non-Indigenous patients, all else (except age) being roughly 
equal. Importantly, however, the age adjusted analysis reveals a significant discrepancy in utilisation 
of angiography for Indigenous patients, a common observation across a number of studies. The results 
suggest the majority of difference observed between Indigenous and non-Indigenous populations, 
with regard to angiography use, is driven by accelerated comorbid disease burden. In essence, at any 
given age, Indigenous subjects have a greater burden of both established vascular disease and 
comorbidities and clinical decision making for patients with high risk NSTEACS may be strongly 
influenced by these factors, more so than by age alone. The mitigation of the disparity in risk could be 
approached with a two-pronged strategy. Improved compliance with guideline-based therapies, 
including angiography and recommended medication, is clearly important. However, a greater 
challenge is to ensure that Indigenous patients with CVD access the tertiary health system at a much 
earlier stage of the disease process than currently occurs (Figure 2).  
Limitations  
There were a number of limitations that should be considered in interpreting our data. Both hospitals 
included in this study have onsite cardiac catheterisation facilities increasing the likelihood of 
angiography. However, a significant proportion of the Indigenous cohort was transferred into the 
study centres from rural locations. There is potential for selection bias and, as such, the rate of 
intervention seen for the Indigenous cohort may be over-estimated, compared to the non-Indigenous 
cohort with a lower rate of transfer from referral centres.  Further, several residual confounders were 
not controlled for namely socio-demographic status, pre-existing cardiovascular risk factors (e.g. 
smoking status) and rurality and remoteness. Finally, a national study of the National Hospital 
Mortality Database reported that the number of Indigenous patients admitted to the hospitals may not 
have been correctly identified
[20]
, suggesting that under-identification maybe problematic in our study.  
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Conclusion   
The younger age and significantly higher risk profile of Indigenous adults presenting to SA hospitals 
with ACS appears to lead to different management decisions, which may well be led by client factors. 
The study findings brings to the forefront the importance of acknowledging the multi-dimensional 
concept of Indigenous status. The fact that a disparity in treatment between Indigenous and non-
Indigenous patients can be explained by other factors (i.e. age, comorbidity, gender) does not mean 
that there is not disparity. Conversely, if a disparity is not explained by other factors, it does not 
necessarily mean that there is causal relationship between Indigenous status and outcome of interest.  
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Age (years) Mean (SEM)  71 (1.0) 77 (0.9) 55 (1.8) 53 (1.6) 
Transfer
†
     
   Metropolitan hospital  65 (33.3) 51 (24.5) 33 (80.5) 37 (84.1) 
Risk stratification     
  Dialysis dependent 2 (10.3) 3 (1.4) 2 (4.9) 7 (15.9) 
  Dyslipidaemia 18 (9.2) 11 (5.3) 4 (9.8) 6 (13.6) 
  Diabetes  63 (32.3) 73 (34.6) 30 (73.2) 35 (79.5) 
  Insulin Dependent 36 (18.5) 21 (10.1) 12 (29.3) 11 (25.0) 
  Hypertension 120 (61.5) 142 (68.3) 28 (68.3) 31 (70.5) 
  Smoker (current)
 ‡
 42 (21.5) 22 (10.5) 21 (51.2) 19 (43.2) 
  Family history of Coronary Artery Disease
§
 9 (22) 7 (16) 14 (7) 12 (6) 
  Known Coronary Artery Disease 109 (55.9) 118 (65.7) 32 (78.0) 36 (81.8) 
  Previous myocardial infarction 32 (16.4) 35 (16.8) 6 (14.6) 6 (13.6) 
  Prior Percutaneous Coronary Intervention 167 (85.6) 160 (76.9) 35 (85.4) 37 (84.1) 
In-hospital procedure     
  Diagnostic coronary angiography 109 (55.9)  85 (40.9) 29 (70.7) 34 (77.3) 
  Percutaneous Cardiac Intervention 64 (32.8) 26 (12.5) 10 (24.4) 16 (36.4) 
    Bare Mental Stent 25 (12.8) 7 (3.4) 6 (14.6) 5 (11.4) 
    Drug Eluting Stent 32 (16.4) 13 (6.25) 4 (9.8) 10 (22.7) 
  Coronary Artery Bypass Graft 8 (4.1) 11 (5.3) 2 (4.9) 3 (6.8) 
  Function Stress Testing
¶
 39 (20.0) 35 (16.8) 10 (24.4) 9 (20.5) 
In-hospital outcomes     
  Death 8 (4.1)  8 (2.6) 0  0 
  New onset of heart failure /acute pulmonary oedema 9 (4.6) 16 (7.7) 1 (2.4) 1 (2.3) 
  New onset of Atrial Fibrillation 22 (11.3) 38 (18.3) 4 (9.8) 3 (6.8) 
  Acute Renal Failure 9 (4.6) 23 (11.1) 2 (4.9) 1 (2.3) 
  Length of in-hospital stay (days) Median (IQR)** 4 (2;7) 4 (2.5;8)  3(2;9) 3 (2;6.5) 
Outcomes at 12 months     
  Rehospitalisation  90 (46.2) 104 (50.0) 14 (34.1) 18 (40.9) 
    Cardiac related hospitalisation 53 (27.2) 64 (30.8) 12 (29.3)  13 (29.5) 
  Revascularisation      
   Percutaneous Coronary Intervention 11 (5.6) 7 (3.4) 0  5 (11.4) 
   Coronary Artery Bypass Graft 9 (4.6) 10 (4.8) 3 (7.3) 3 (6.8) 
  Death 2 (1.0)  6 (2.9) 1 (2.4) 3 (6.8) 
Source: SA NSTEACS Retrospective Case Note Cohort Study 
The study cohort are patients who were admitted to two public tertiary metropolitan hospitals in South Australia. 
The results are presented as counts (percentages), except for age (years) Mean (Standard Error Mean) and length of stay**in 
hospital that is reported as a median (interquartile range). 
*Indigenous participant refers to Aboriginal and Torres Strait Islander Australians. Indigenous status was recorded if identified 
by the patient on admission. 
†Transferred to metropolitan hospital refers to the patient being transferred from other sites to the study centre for a cardiac 
investigation and/or treatment such as diagnostic coronary angiogram or revascularisation. 
 ‡Current smoker is defined as any smoking within the past 12 months. 
§Family history of coronary artery disease was reported by the patient i.e. first degree relative under the age of 60 years who has 
had a vascular disease/condition diagnosed. 
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Table 2: Comorbidity and risk profile of study participants by age- group and ethnicity 
 Age groups and Indigenous Status  
 18-49 years n=52  50-64 years n=123 65+ years n=313 












Comorbidities       
  Dialysis 0 2 (6.5) 0 6 (14.3) 5 (1.7) 1 (8.3) 
  Dyslipidaemia 0 5 (16.1) 6 (7.4) 2 (4.8) 23 (7.6) 3 (25.0) 
  Diabetes 3 (14.3) 19 (61.3) 29 (35.8) 35 (83.3) 104 (34.6) 11 (91.7) 
  Hypertension 9 (42.9) 19 (61.3) 46 (56.8) 30 (71.4) 207 (68.8) 12 (100) 
  Known Coronary Artery Disease 6 (28.6) 21 (67.8) 38 (46.9) 35 (83.3) 183 (60.8) 12 (100) 
Risk Factors       
  Current Smoker
†
 13 (61.9) 20 (64.5) 18 (22.2) 15 (35.7) 33 (11.0) 5 (41.7) 
  Family history
‡
 6 (28.6) 10 (32.3) 8 (9.9) 5 (11.9) 12 (4.0) 1 (8.3) 
  Prior Myocardial Infarction 3 (14.3) 3 (9.7) 15 (18.5) 6 (14.3) 49 (16.3) 3 (25.0) 
  Prior Percutaneous Coronary Intervention 16 (76.2) 29 (93.5) 70 (86.4) 33 (78.6) 241 (80.1) 10 (83.3) 
  Prior Coronary Artery Bypass Graft 1 (4.8) 4 (12.9) 7 (8.6) 5 (11.9) 47 (15.6) 1  (8.3) 
  History of Atrial Fibrillation 1 (4.8) 1 (3.2) 16 (19.8) 1 (2.4) 17 (5.6) 2 (16.7) 
SA NSTEACS Retrospective Case Note Cohort Study 
The study cohort are patients who were admitted to two public tertiary metropolitan hospitals in South Australia from Jan 2008-Dec 2009 
*Indigenous participant refers to Aboriginal and Torres Strait Islander Australians. Indigenous status was recorded if identified by the patient on 
admission. 
The results are presented as counts (percentages) and all percentages were rounded up to the nearest integer. 
†Current smoker is defined as any smoking within the past 12 months. 
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Table 3 Study population characteristics and likelihood of receiving a diagnostic coronary angiogram 
Study Factor  Angiogram Rate  95% CI Sig. 
  N % Ratio RR  
Demographics       
Age                  <50  45 86.5 1.00   
                        50-64  86 70.0 0.81 0.70;0.93 0.004 
                        65+  126 40.3 0.47 0.38;0.56 <0.001 
Gender     Male  138 58.5 1.00   
                        Female  119 47.2 0.81 0.66;0.99 0.035 
Ethnicity         Non-Indigenous  194 48.1 1.00   
                        Indigenous‡  63 74.1 1.54 1.31;1.81 <0.001 
Transfer to Metropolitan Hospital No 105 34.8 1.00   
 Yes 152 81.7 2.35 1.95;2.83 <0.001 
Comorbidities       
  Dialysis No 247 52.9 1.00   
 Yes 8 57.1 1.09 0.66;1.80 0.745 
  Dyslipidaemia No 231 51.5 1.00   
 Yes 26 66.7 1.30 1.04;1.16 0.020 
  Diabetes No 144 50.2 1.00   
 Yes 113 56.2 1.12 0.95;1.32 0.166 
  Hypertension No 87 53.1 1.00   
 Yes 169 52.6 0.99 0.83;1.18 0.933 
  Known Coronary Artery Disease No 119 61.7 1.00   
 Yes 138 46.8 0.76 0.63;0.91 0.002 
Risk Factors       
  Current Smoker No 182 47.4 1.00   
 Yes 75 72.1 1.52 1.29;1.79 <0.001 
  Prior Myocardial Infarction No 228 55.8 1.00   
 Yes 29 36.7 0.66 0.50;0.87 0.004 
  Prior Percutaneous Coronary Intervention No 23 25.8 1.00   
 Yes 234 58.6 2.27 1.59;3.24 <0.001 
  Prior Coronary Artery Bypass Graft No 235 55.6 1.00   
 Yes 22 33.8 0.61 0.43;0.86 0.005 
Cardiac biomarker       
  Elevated Troponin >0.02ng/mL
¶
   No 107 50.7 1.00   
 Yes 150 54.1 1.07 0.90;1.27 0.461 
Revascularisation       
  Percutaneous Coronary Intervention No 141 37.9 1.00   
 Yes 116 100.00 2.64 2.28;3.06 <0.001 
  Coronary Artery Bypass Graft No 235 50.7 1.00   
 Yes 22 91.7 1.81 1.57;2.09 <0.001 
In-hospital death       
  Death No 256 54.2 1.00   
 Yes 1 6.3 0.12 0.12;0.79 0.027 
Outcome at 12 months       
  Rehospitalisation No 160 61.1 1.00   
 Yes 97 42.9 0.70 0.58;0.85 <0.001 
  Percutaneous Coronary Intervention No 242 52.0 1.00   
 Yes 15 65.2 1.25 0.91;1.73 0.172 
  Coronary Artery Bypass Graft No 239 51.6 1.00   
 Yes 18 72.0 1.39 1.07;1.82 0.015 
  Death No 253 53.2 1.00   
 Yes 4 33.3 0.63 0.27;1.46 0.280 
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SA NSTEACS Retrospective Case Note Cohort Study *Australian Guidelines for the Management of Acute Coronary 
Syndromes 2006 specifies the eligibility criteria for diagnostic coronary angiography. 
All percentage values are rounded up to nearest integer. †The results are presented as percentages (counts), except for 
Age (year) which is reported as mean (Standard Error of the Mean). 
‡Indigenous participant refers to Aboriginal and Torres Strait Islander Australians. Indigenous status was recorded if 
identified by the patient on admission. 
†Transfer to metropolitan hospital refers to the patient being transferred from other sites to the study centre for a 
cardiac investigation and/or treatment such as diagnostic coronary angiogram or revascularisation. 
§Smoker is defined as any smoking within the last 12 months.  
¶An elevated troponin was defined as a value >0.02 ng/mL per ESC. Current international criteria for the diagnosis of 
myocardial infarction have a strong emphasis on biomarkers, specifically troponin, given its high sensitivity, and in 
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Table 4 Study population characteristics and likelihood of receiving recommended medications on 
discharge 
Study Factor  Medication Rate  95% CI Sig. 
  N % Ratio RR  
Demographics       
Age             <50  42 80.8 1.00   
                    50-64  94 76.4 0.95 0.81;1.10 0.478 
                    65+  165 52.7 0.65 0.54;0.78 <0.001 
Gender Male  162 68.6 1.00   
                    Female  139 55.2 0.80 0.71;0.91 0.001 
Ethnicity     Non-Indigenous  229 56.8 1.00   
                   Indigenous‡   72 84.7 1.49 1.30;1.71 <0.001 
Transfer to Metropolitan Hospital No 156 51.7 1.00   
 Yes 145 78.0 1.51 1.33;1.71 <0.001 
Comorbidities       
  Dialysis No 288 61.3 1.00   
 Yes 12 85.7 1.40 1.12;1.75 0.003 
  Dyslipidaemia No 269 59.9 1.00   
 Yes 32 82.0 1.37 1.16;1.61 <0.001 
  Diabetes No 166 57.8 1.00   
 Yes 135 67.2 1.16 1.00;1.34 0.046 
  Hypertension No 98 59.8 1.00   
 Yes 203 63.2 1.06 0.93;1.21 0.407 
  Known Coronary Artery Disease No 121 62.7 1.00   
 Yes 180 61.0 0.97 0.85;1.12 0.699 
Risk Factors       
  Current Smoker No 220 57.3 1.00   
 Yes 81 77.9 1.36 1.18;1.56 <0.001 
  Prior Myocardial Infarction No 256 62.6 1.00   
 Yes 45 57.0 0.91 0.76;1.09 0.311 
  Prior Percutaneous Coronary Intervention No 40 44.9 1.00   
 Yes 261 65.4 1.46 1.17;1.81 0.001 
  Prior Coronary Artery Bypass Graft No 262 61.9 1.00   
 Yes 39 60.0 1.03 0.81;1.30 0.792 
Cardiac biomarker       
  Elevated Troponin >0.02ng/mL
¶
   No 140 66.4 1.00   
 Yes 161 58.1 0.88 0.75;1.02 0.095 
Revascularisation       
  Percutaneous Coronary Intervention No 200 53.7 1.00   
 Yes 101 87.0 1.62 1.45;1.81 <0.001 
  Coronary Artery Bypass Graft No 282 60.8 1.00   
 Yes 19 79.2 1.30 1.05;1.61 0.015 
Outcome at 12 months       
  Rehospitalisation No 166 63.4 1.00   
 Yes 135 59.7 0.94 0.83;1.07 0.366 
  Percutaneous Coronary Intervention No 283 60.9 1.00   
 Yes 18 78.3 1.29 1.01;1.64 0.041 
 Coronary Artery Bypass Graft No 286  61.8 1.00   
 Yes 15 60.0 0.97 0.69;1.37 0.868 
  Death No 292  61.3 1.00   
 Yes 9 75.0 1.22 0.90;1.66 0.196 
SA NSTEACS Retrospective Case Note Cohort Study  
*Australian guidelines for the management of acute coronary syndromes 2006 specify the eligibility criteria for 
recommended medication on patient discharge. 
This article is protected by copyright. All rights reserved. 
All percentage values are rounded up to nearest integer.  
‡Indigenous participant refers to Aboriginal and Torres Strait Islander Australians. Indigenous status was recorded 
if identified by the patient on admission. 
†Transfer to metropolitan hospital refers to the patient being transferred from other sites to the study centre for a 
cardiac investigation and/or treatment such as diagnostic coronary angiogram or revascularisation. 
§Smoker is defined as any smoking within the last 12 months.  
¶An elevated troponin was defined as a value >0.02 ng/mL per ESC. Current international criteria for the diagnosis 
of myocardial infarction have a strong emphasis on biomarkers, specifically troponin, given its high sensitivity, and 
in particular specificity for myonecrosis 
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Table 5: Multivariate analysis on the likelihood of angiography and recommended medications on 
discharge by ethnicity 
 Model-based estimate 
Outcome of interest Model 1* Model 2§ Model 3† 
 RR 95% CI Sig. RR 95% CI Sig. RR 95% CI Sig. 
Angiography¶          
  Non-Indigenous Base Reference        
  Indigenous‡ 
 
1.54 1.31;1.81 <0.001                                        0.91 0.76;1.09 0.305 0.92 0.75;1.13 0.449 
Medications§§          
  Non-Indigenous  Base Reference       
  Indigenous 1.49 1.30;1.71 <0.001 1.22 1.06;1.42 0.006 1.19 1.01;1.40 0.035 
          
SA NSTEACS Retrospective Case Note Cohort Study 
*Model 1 (crude) The risk ratio is derived from the matched bivariate analysis, with no adjustment for age, gender or propensity score 
§ Model 2 (adjusted) The risk ratio is derived from a matched cluster that is adjusted for age (current practice for adjusting for age) and 
gender. 
†Model 3 (adjusted) The risk ratio is derived from a matched cluster that is adjusted for age, gender and propensity score. The propensity 
score includes cardiovascular risk factors (hypertension, diabetes, smoking status), history previous infarction, percutaneous or surgical 
revascularisation, hemodynamic condition (positive troponin release).  
¶ Australian Guidelines for the management of Acute Coronary Syndromes 2006 specifies the eligibility criteria for diagnostic coronary 
angiography and describes the recommended medication on patient discharge. 
‡ Indigenous participant refers to Aboriginal and Torres Strait Islander Australians. Indigenous status was recorded if identified by the 
patient on admission. 
§§Australian guidelines for the management of acute coronary syndromes 2006 specify the eligibility criteria for recommended discharge 
medications i.e. aspirin, clopidogrel, angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist, β blocker and statin. If 
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Figure 1 Flow chart of study population, matched variables and outcomes of interest. 
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Figure 2 A schematic of the natural history of cardiovascular disease throughout life demonstrating 
that Indigenous patients are more likely to present at a later stage of disease than non-Indigenous 
subjects. 
 
 
